Cargando…
Propranolol sensitizes prostate cancer cells to glucose metabolism inhibition and prevents cancer progression
Propranolol, a widely used non-selective beta-adrenergic receptor blocker, was recently shown to display anticancer properties. Its potential to synergize with certain drugs has been also outlined. However, it is necessary to take into account all the properties of propranolol to select a drug that...
| Autores principales: | , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Nature Publishing Group UK
2018
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5935740/ https://www.ncbi.nlm.nih.gov/pubmed/29728578 http://dx.doi.org/10.1038/s41598-018-25340-9 |